May 4, 2020
Kala re-applies Eysuvis to FDA for Dry Eye Disease
Kala Pharmaceuticals has resubmitted its New Drug Application to the FDA for Eysuvis, its product candidate to treat dry eye disease.
Pharmaceuticals, Biotechnology and Life Sciences
Category: North America
May 4, 2020
Adare Pharmaceuticals, Inc. Acquires Orbis Biosciences
Adare Pharmaceuticals has bought a technology company Orbis Biosciences, aiming to enhance its own Pharmaceutical Technologies business, creating products for global pharma, animal health and OTC markets.
May 4, 2020
Teva, Celltrion Healthcare launch Truxima in US for Rheumatoid Arthritis, Rituxan biosimilar
Truxima, the only US biosimilar to Rituxan, is also now available for the treatment of Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA).
May 3, 2020
Canada backs AbCellera with $175.6M to seek Cov-19 solutions
AbCellera’s world-leading drug discovery technology identifies antibodies for potential use in drugs to treat and prevent COVID-19 got cash support from Canadian Government of $175.6 million.
May 2, 2020
Gilead’s investigational COV-19 treatment Remdesivir gets FDA’s emergency use authorization
Gilead get’s authorization of emergency use of Remdesivir to treat hospitalized patients with severe COVID-19 disease in the United States.
May 2, 2020
Revance, Mylan Biosimilar to Botox postpon program decision
Revance, Mylan Biosimilar to Botox postpon program decision to aftr April
May 1, 2020
Moderna, Lonza work on Moderna’s Corona Vaccine
Moderna has engaged with Lonza to work on its novel coronavirus vaccine, with a goal to enable manufacturing of up to 1 billion doses per year, noting that technology transfer is expected to begin in June 2020.
May 1, 2020
AMRI Increases Hydroxychloroquine Sulfate API Production in U.S. to Meet Potential COVID-19 Demand
ALBANY, N.Y.–(BUSINESS WIRE)–AMRI today announced its ongoing commitment to do its part in support of public health needs amidst the…
April 30, 2020
Novocure Q1 net revenues $101.8 million, 39% up
Novocure has posted quarterly net revenues of $101.8 million, representing 39 percent growth versus the first quarter 2019 and 3 percent growth versus the fourth quarter 2019.
April 30, 2020
Nicoya support researchers during COVID-19
Nicoya, a leading provider of advanced analytical instruments for the biotechnology and pharmaceutical industries, announced today that they will be offering Surface Plasmon Resonance (SPR) technical support to all researchers – at no cost – during COVID-19.